Abdominal Obesity as a Predictive Factor of Nonalcoholic Fatty Liver Disease Assessed by Ultrasonography and Transient Elastography in Polycystic Ovary Syndrome and Healthy Women

Table 3

Univariate analysis of various factors for NAFLD assessed by abdominal US in women with and without NAFLD.

Factors	No NAFLD; n(%)	NAFLD; n(%)	Odd ratios	95 %CI	P-value
WC
≤ 80	21(72.41)	8(27.59)	1	-	0.002
> 80	11(32.35)	23(67.65)	5.49	1.66- 18.11
BMI
< 25	20(68.97)	9(31.03)	1	-	0.008
≥ 25	12(35.29)	22(64.71)	4.07	1.32- 12.60
FBS
< 100	31(54.39)	26(45.61)	1	-	0.104
≥ 100	1(16.67)	5(83.33)	5.96	0.61- 58.51
2 hrs Glucose
< 140	29(52.73)	26(47.27)	1	-	0.474
≥ 140	3(37.50)	5(62.50)	1.86	0.40-8.73
Biochemical HA
No	25(59.52)	17(40.48)	1	-	0.064
Yes	7(33.33)	14(66.67)	2.94	0.94-9.20
Clinical HA
No	19(59.38)	13(40.63)	1	-	0.166
Yes	13(41.94)	18(58.06)	2.02	0.72-5.65
Total HA
No	16(64.00)	9(36.00)	1	-	0.123
Yes	16(42.11)	22(57.89)	2.44	0.83-7.15
Insulin Resistance(IR)
No	21(63.64)	12(36.36)	1	-	0.045
Yes	11(36.67)	19(63.33)	3.02	1.03-8.85
Abnormal Glucose
No	28(60.87)	18(39.13)	1	-	0.015
IGT	4(28.57)	10(71.43)	3.89	0.99-15.23
DM	0(0.00)	3(100.00)	4.55	0.48-43.07
TG
< 150	31(55.36)	25(44.64)	1	-	0.053
≥ 150	1(14.29)	6(85.71)	7.44	0.76-72.47
HDL
< 50	10(31.25)	22(68.75)	5.38	1.65-17.56	0.002
≥ 50	22(70.97)	9(29.03)	1	-
LDL
≤ 130	19(63.33)	11(36.67)	1	-	0.058
> 130	13(39.39)	20(60.61)	2.66	0.92-7.66
Metabolic Syndrome
No	31(57.41)	23(42.59)	1	-	0.013
Yes	1(11.11)	8(88.89)	10.78	1.09-106.31
PCOS					0.479
No	12(57.14)	9(42.86)	1	-
Yes	20(47.62)	22(52.38)	1.47	0.50-4.27